New Delhi [India], December 10 (ANI): Bhutan's Ambassador to India on Wednesday said that the Covid-19 vaccines in India will benefit most countries, as they would be the easiest to administer and transport.

Speaking to foreign envoys onboard a plane to New Delhi, Ambassador Vetsop Namgyel said: "Vaccines in India are the ones which will be easiest to administer and transport. Most countries will benefit from it. India is known to produce in bulk quantities, once approved it can be rolled out quickly."

Also Read | Barack Obama Did Not Snub PM Narendra Modi on Twitter Over Farmers’ Protest; Fact-Check Debunks Fake News Spread Through Morphed Image.

Namgyel was among the 60 foreign heads of missions who visited the facilities of two pharmaceutical firms working on Covid-19 vaccines- the Bharat Biotech and the Biological E.

F Svane, Ambassador of Denmark to India, said that India is not working for commercial or national interest but is also working for countries around the world.

Also Read | Turkey Refuses to Buy Russian COVID-19 Vaccine Citing ‘Lack of Good Practice’, Kremlin Reacts.

While praising Prime Minister Narendra Modi, Mahima Datla, the Managing Director of the Biological E Ltd, said it is a testament to PM Modi's vision who's not only showcasing collaboration but is keen to ensure that Indian companies play a vital role in delivering vaccines around the world.

Sources had informed that there is a lot of interest in India's vaccine development efforts.

PM Modi has said that India's vaccine production and delivery capacity will be used to help all humanity in fighting this crisis.

He visited the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad, and Serum Institute of India in Pune on November 28 to conduct an extensive review of the vaccine development and manufacturing process.

Bharat Biotech had on Monday applied for emergency use authorisation for its indigenously developed Covid-19 vaccine 'Covaxin' to Drugs Controller General of India (DCGI).

It is the second Indian company to apply for emergency use authorisation after the Serum Institute of India applied for such use for the vaccine developed by Oxford University and AstraZeneca. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)